WGS
GeneDx Holdings Corp. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +30.0% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 88 | -5 | 15.43M | $1.06B | +10 | −14 |
| Q1 2026 | 95 | +2 | 15.21M | $977.50M | +14 | −13 |
| Q4 2025 | 94 | +1 | 15.07M | $1.96B | +3 | −1 |
| Q3 2025 | 16 | -1 | 7.41M | $798.15M | +2 | −4 |
| Q2 2025 | 15 | -1 | 4.67M | $430.80M | +1 | −2 |
| Q1 2025 | 13 | 0 | 2.11M | $186.46M | n/a | n/a |
| Q4 2024 | 13 | +1 | 1.90M | $146.41M | +2 | −1 |
| Q3 2024 | 11 | +4 | 1.69M | $71.81M | +4 | n/a |
| Q2 2024 | 7 | n/a | 992.14K | $25.94M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 574.44K | +84.5% | $24.38M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 377.63K | +8.8% | $16.03M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Point72 Asset Management ✦ | 293.67K | +87.4% | $12.46M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Renaissance Technologies ✦ | 93.57K | +3.5% | $3.97M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 87.39K | New | $3.71M | 0.0% | New | 1 | SEC ↗ ×3 |
| 6 | Marshall Wace ✦ | 86.47K | New | $3.67M | 0.0% | New | 1 | SEC ↗ ×2 |
| 7 | T. Rowe Price ✦ | 63.58K | +34.8% | $2.70M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 40.42K | +3.1% | $1.72M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 31.39K | New | $1.33M | 0.0% | New | 1 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 29.80K | +229169.2% | $1.26M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 11 | Gotham Asset Management ✦ | 13.48K | New | $572,006 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $3.71M | 0.0% |
| Marshall Wace | $3.67M | 0.0% |
| D. E. Shaw & Co. | $1.33M | 0.0% |
| Gotham Asset Management | $572,006 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 240 holders, 31.22M shares, $1.98B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 3.04K sh · $300,846
Officer · 1.08K sh · $106,816
Officer, Director · 1.65K sh · $155,337
Officer, Director · 148 sh · $14,120
Officer, Director · 1.52K sh · $147,774
Officer, Director · 4.14K sh · $406,936
Officer · 586 sh · $55,235
Officer · 52 sh · $4,961
Officer · 541 sh · $52,423
Officer · 1.47K sh · $144,457
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
1.8% of class · View original SEC filing ↗